Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

NCT ID: NCT05949281

Last Updated: 2026-01-26

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-29
• Study Completion Date: 2031-01-15

Brief Summary

The aim of this clinical trial is to evaluate if colchicine in addition to standard of care improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes. Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for 26 weeks with the possibility of an additional 26 week extension of the intervention period. After the treatment period, there will a 5-year follow-up on all available outcome measures via electronic patient records for those who took part in the extension.

Detailed Description

The current study aims to evaluate the efficacy of 0.5 mg colchicine once-daily added to existing standard of care in persons with established type 1 diabetes, existing arteriosclerotic cardiovascular disease (CVD) or at high risk thereof and C-reactive protein (CRP) ≥ 2 mg/L. Specifically, the primary objective is to determine the effect of colchicine (0.5 mg/daily) on levels of CRP (as assessed by high-sensitivity assays) as compared with placebo following 26-52 weeks of treatment. Additionally, the study will investigate the short and long-term effects of colchicine treatment on other markers of CVD and inflammation, markers of metabolism and markers of glycemic control in type 1 diabetes, including glycated hemoglobin (HbA1c), time spent in hypoglycemia (level 1 glucose readings 3.0-3.8 mmol/L and level 2 glucose readings < 3.0 mmol/L), target glycemia (glucose readings 3.9-10 mmol/L) and hyperglycemia (level 1 glucose readings 10.1-13.9 mmol/L and level 2 glucose readings > 13.9 mmol/L) together with measures of glycemic variability evaluated by continuous glucose monitoring (CGM), insulin dosage, risk of hypoglycemia, risk of diabetic ketoacidosis and body weight. During the 5-year follow-up, we will collect all available outcome measures via electronic patient records.

Conditions

Type 1 Diabetes; Cardiovascular Diseases; Chronic Inflammation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Colchicine

Colchicine tablet 0.5 mg once-daily

Group Type: ACTIVE_COMPARATOR

Colchicine 0.5 MG Oral Tablet

Intervention Type: DRUG

Colchicine 0.5 mg once-daily

Placebo

Placebo tablet once-daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo tablet once-daily

Interventions

Colchicine 0.5 MG Oral Tablet

Colchicine 0.5 mg once-daily

Intervention Type: DRUG

Placebo

Placebo tablet once-daily

Intervention Type: DRUG

Other Intervention Names

Colrefuz

Eligibility Criteria

Inclusion Criteria

• Type 1 diabetes for more than five years according to World Health Organization criteria
• Age 35-80 years
• Hemoglobin A1c < 80 mmol/mol
• Stable insulin therapy (defined as no change in insulin brand and no newly initiated continous subcutaneus insulin infusion (CSII) or multiple-daily injection (MDI) therapy) and, if applicable, stable usage of glucose monitoring technology (e.g., continous glucose monitor (CGM) or intermittently scanned CGM) ≥ 3 months with either MDI or CSII
• CRP ≥ 2 mg/L (measured by high-sensitivity assay)
• eGFR > 50 mL/min/L/1.73 m^2
• Either stable arteriosclerotic cardiovascular disease (ASCVD) (as defined by ischemic heart disease including previous acute myocardial infarction, acute coronary syndrome and coronary revascularization; other arterial revascularization procedures; stroke and transient ischemic attack; aortic aneurysm; peripheral arterial disease, including carotid atherosclerosis)
• and/or risk of cardiovascular (CV) death > 5 % within 10 years (i.e., high or very high CV risk) as defined by the European Society of Cardiology or 10-year CV risk ≥ 20 % (i.e., high CV risk) as according to 'Steno Type 1 Diabetes Risk Engine' (https://steno.shinyapps.io/T1RiskEngine/)

Exclusion Criteria

• Hypoglycemia unawareness (inability to register low blood glucose) am modum Pedersen-Bjergaard, unless usage of CGM with alarm function
• Liver disease with elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal (measured at screening with the possibility of one repeat analysis within seven days, and the last measured value as being conclusive)
• History of cirrhosis, chronic active hepatitis or severe hepatic disease
• Inflammatory bowel disease or chronic diarrhea
• Pre-existing progressive neuromuscular disease or persons with creatinine kinase levels > three times the upper limit of normal (measured at screening with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)
• Cancer or lymphoproliferative disease unless in complete remission for > 5 years
• Immunosuppressive therapy or state of chronic immunodeficiency, including infection with human immunodeficiency virus (HIV)
• Blood dyscrasias (e.g., myelodysplastic syndromes or related hematological disorders)
• Leukocyte cell count < 3.0 X 10^9/L
• Thrombocyte count < 110 X 10^9/L
• Systemic (oral or intravenous), long-term steroid therapy (topical or inhaled steroids are allowed)
• Hemodialysis or peritoneal dialysis therapy (since colchicine cannot be removed by dialysis or exchange transfusion)
• Renal or hepatic impairment treated with a P-gp inhibitor or a strong CYP3A4 inhibitor
• Intake of grapefruit juice during trial participation
• Other concomitant disease or treatment that according to the investigator's assessment makes the person unsuitable for study participation
• Alcohol/drug abuse
• Fertile women not using hormonal (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormone intrauterine devices (IUD), hormonal vaginal ring or transdermal hormonal patch), chemical (copper IUD) or mechanical (condom, femidom, sterilization) contraceptives
• Pregnant or nursing women
• On permanent treatment with colchicine that is not discontinued within 30 days of screening visit
• Known or suspected hypersensitivity to colchicine
• Receipt of any investigational drug within 30 days prior to screening visit
• Simultaneous participation in any other clinical intervention trial

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Copenhagen

OTHER

Sponsor Role: collaborator

Juvenile Diabetes Research Foundation

OTHER

Sponsor Role: collaborator

Asger Lund, MD

OTHER

Sponsor Role: lead

Responsible Party

Asger Lund, MD

Ass. Professor, MD, PhD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Asger B. Lund, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Center for Clinical Metabolic Research, Gentofte Hospital, Denmark

Locations

Center for Clinical Metabolic Research, Gentofte Hospital

Hellerup, Capital Region, Denmark

Countries

Denmark

Other Identifiers

2022-502038-23-00

Identifier Type: -

Identifier Source: org_study_id